Chief Development Officer

Margaret Karow is a founder of Tentarix and brings over 25 years of experience in the generation and engineering of protein therapeutics. Prior to joining Tentarix, Margaret was the CSO for Gensun Biopharma, and before that she was the Senior Vice President of Pre-Clinical Development for Xilio Therapeutics (formerly Akrevia Therapeutics) where her contributions helped secure $30M Series A funding. Before joining Xilio Therapeutics, she was an Executive Director at Amgen for 10 years, and held multiple positions including leadership roles for Biosimilars Process Development, Amgen Thousand Oaks Protein Sciences, Biologics Optimization, and Site Head for Amgen Burnaby, Canada. Margaret started her career in biotech at Regeneron, over the course of a decade, had a variety of roles including Vice President and co-lead for the development of the VelocImmune mouse platform.

Margaret holds a B.A. in Molecular, Cellular and Developmental Biology from the University of Colorado, Boulder and a Ph.D. in Biology from the University of Utah.